# PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

> **NCT00511043** · PHASE2 · TERMINATED · sponsor: **David Rizzieri, MD** · enrollment: 20 (actual)

## Conditions studied

- Lymphoma, Large-Cell, Diffuse

## Interventions

- **DRUG:** PTK787

## Key facts

- **NCT ID:** NCT00511043
- **Lead sponsor:** David Rizzieri, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** 2009-08
- **Final completion:** 2010-06
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Manufacturer stopped drug development
- **Last updated:** 2014-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00511043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00511043, "PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma". Retrieved via AI Analytics 2026-09-10 from https://api.ai-analytics.org/clinical/NCT00511043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*